This article is more than 5 years old. Information may no longer be current.
Aton Pharma broadens distribution program for insertable dry eye treatment
Click Here to Manage Email Alerts
LAWRENCEVILLE, N.J. — Aton Pharma has launched an expanded, comprehensive distribution program for its Lacrisert dry eye treatment, which incorporates sampling, reimbursement assistance and patient education, according to a press release from the company.
Lacrisert (hydroxypropyl cellulose ophthalmic insert) is a preservative-free, sustained release, once-daily prescription insert intended to help retain moisture, stabilize the tear film and lubricate the eye, the release said.
"Once the patient inserts Lacrisert in the morning, it usually lasts the entire day, so it's something that is helpful to offer patients suffering from chronic pain from dry eye disease," Penny A. Asbell, MD, FACS, OSN Contact Lenses Section Editor, said in the release. "One of the advantages of Lacrisert is that it is preservative- free."
The insert is placed into the inferior cul-de-sac of the eye, where it provides lubrication and protection to the ocular surface. Lacrisert may also help "slow, stop or reverse further damage to the corneal surface" in some patients, the release said.